214 related articles for article (PubMed ID: 28747219)
41. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
Ardissino G; Testa S; Possenti I; Tel F; Paglialonga F; Salardi S; Tedeschi S; Belingheri M; Cugno M
Am J Kidney Dis; 2014 Oct; 64(4):633-7. PubMed ID: 24656451
[TBL] [Abstract][Full Text] [Related]
42. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.
Bharthuar A; Egloff L; Becker J; George M; Lohr JW; Deeb G; Iyer RV
Cancer Chemother Pharmacol; 2009 Jun; 64(1):177-81. PubMed ID: 19116715
[TBL] [Abstract][Full Text] [Related]
43. Gemcitabine-induced hemolytic uremic syndrome: a case report.
Brodowicz T; Breiteneder S; Wiltschke C; Zielinski CC
J Natl Cancer Inst; 1997 Dec; 89(24):1895-6. PubMed ID: 9414181
[No Abstract] [Full Text] [Related]
44. Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab.
Andries G; Karass M; Yandrapalli S; Linder K; Liu D; Nelson J; Pawar R; Chugh S
Exp Hematol Oncol; 2017; 6():4. PubMed ID: 28101432
[TBL] [Abstract][Full Text] [Related]
45. [Hemolytic uremic syndrome induced by gemcitabine. A poorly recognized complication?].
Graas MP; Houbiers G; Demolin G; Stultiens A; Focan C
Rev Med Liege; 2012 Dec; 67(12):644-8. PubMed ID: 23342875
[TBL] [Abstract][Full Text] [Related]
46. Gemcitabine-associated thrombotic microangiopathy.
Humphreys BD; Sharman JP; Henderson JM; Clark JW; Marks PW; Rennke HG; Zhu AX; Magee CC
Cancer; 2004 Jun; 100(12):2664-70. PubMed ID: 15197810
[TBL] [Abstract][Full Text] [Related]
47. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
Wijnsma KL; Duineveld C; Wetzels JFM; van de Kar NCAJ
Pediatr Nephrol; 2019 Nov; 34(11):2261-2277. PubMed ID: 30402748
[TBL] [Abstract][Full Text] [Related]
48. Eculizumab for atypical hemolytic uremic syndrome in pregnancy.
Ardissino G; Wally Ossola M; Maria Baffero G; Rigotti A; Cugno M
Obstet Gynecol; 2013 Aug; 122(2 Pt 2):487-489. PubMed ID: 23884270
[TBL] [Abstract][Full Text] [Related]
49. Livedo racemosa and hemolytic uremic syndrome induced by gemcitabine.
Tognetti L; Garosi G; Rongioletti F; Fimiani M; Rubegni P
Int J Dermatol; 2016 Oct; 55(10):e555-6. PubMed ID: 27125732
[No Abstract] [Full Text] [Related]
50. [A 42 year old patient with bilateral loss of sight and hypertension. Gemcitabine-associated thrombotic microangiopathy (TMA)].
Schmidt A; Schwella N; Helmchen U; von Renteln D; Caca K
Internist (Berl); 2008 Aug; 49(8):989-90, 992-4. PubMed ID: 18427761
[TBL] [Abstract][Full Text] [Related]
51. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.
Nga HS; Palma LMP; Ernandes Neto M; Fernandes-Charpiot IMM; Garcia VD; Kist R; Miranda SMC; Macedo de Souza PA; Pereira GM; de Andrade LGM
PLoS One; 2021; 16(11):e0258319. PubMed ID: 34748552
[TBL] [Abstract][Full Text] [Related]
52. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
Olson SR; Lu E; Sulpizio E; Shatzel JJ; Rueda JF; DeLoughery TG
Am J Nephrol; 2018; 48(2):96-107. PubMed ID: 30110670
[TBL] [Abstract][Full Text] [Related]
53. Early initiation of eculizumab therapy for Streptococcus pneumoniae-associated hemolytic uremic syndrome.
See J; Bou Matar R; Baloglu O; Latifi SQ; Talati R; Agarwal HS
Pediatr Blood Cancer; 2021 Feb; 68(2):e28589. PubMed ID: 32672848
[No Abstract] [Full Text] [Related]
54. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome.
Vilalta R; Lara E; Madrid A; Chocron S; Muñoz M; Casquero A; Nieto J
Pediatr Nephrol; 2012 Dec; 27(12):2323-6. PubMed ID: 22890512
[TBL] [Abstract][Full Text] [Related]
55. Is thrombotic microangiopathy associated with antitumoral activity?
Chopin N; Alexandre J; Chapron C; Moachon L; Goldwasser F
Gynecol Oncol; 2006 Jun; 101(3):549-50. PubMed ID: 16527338
[No Abstract] [Full Text] [Related]
56. Gemcitabine-induced thrombotic microangiopathy treated with eculizumab: a case report.
Van den Eeckhaut L; Hannon H; Schurgers M; Monsaert E; Claes K
J Gastrointest Oncol; 2022 Dec; 13(6):3314-3320. PubMed ID: 36636054
[TBL] [Abstract][Full Text] [Related]
57. Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: a report of two cases.
Tanaka K; Fujita N; Hibino S
CEN Case Rep; 2020 Aug; 9(3):247-251. PubMed ID: 32240525
[TBL] [Abstract][Full Text] [Related]
58. Gemcitabine-associated livedoid thrombotic microangiopathy with associated sclerema neonatorum-like microscopic changes.
Mir-Bonafé JM; Román-Curto C; Santos-Briz A; Cañueto J; Fernández-López E; Unamuno P
J Cutan Pathol; 2012 Jul; 39(7):707-11. PubMed ID: 22612305
[TBL] [Abstract][Full Text] [Related]
59. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
Galbusera M; Noris M; Gastoldi S; Bresin E; Mele C; Breno M; Cuccarolo P; Alberti M; Valoti E; Piras R; Donadelli R; Vivarelli M; Murer L; Pecoraro C; Ferrari E; Perna A; Benigni A; Portalupi V; Remuzzi G
Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
[TBL] [Abstract][Full Text] [Related]
60. [Gemcitabine-induced thrombotic microangiopathy].
Teixeira L; Debourdeau P; Zammit C; Estival JL; Pavic M; Colle B
Presse Med; 2002 Apr; 31(16):740-2. PubMed ID: 12148351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
